AbbVie Inc. (ABBV)
After hours:
| Previous close | 156.31 |
| Open | 156.65 |
| Bid | 160.54 x 800 |
| Ask | 161.14 x 1000 |
| Day's range | 156.20 - 161.64 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,598,953 |
| Market cap | 284.729B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | 47.99 |
| EPS (TTM) | 3.36 |
| Earnings date | 25 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | 6.20 (3.97%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | 182.92 |
ZacksGilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
PR NewswireAbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of risankizumab (SKYRIZI®) for the treatment of adults with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional or biologic therapy. The recommended induction dose is 1200 mg intravenous (IV), followed by a maintenance dose of 180 mg or
ZacksAre Options Traders Betting on a Big Move in AbbVie (ABBV) Stock?
Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.
